...
首页> 外文期刊>Circulation journal >Prasugrel, a Third-Generation P2Y12 Receptor Antagonist, in Patients With Coronary Artery Disease Undergoing Elective Percutaneous Coronary Intervention - Phase III, Randomized, Double-Blind Study -
【24h】

Prasugrel, a Third-Generation P2Y12 Receptor Antagonist, in Patients With Coronary Artery Disease Undergoing Elective Percutaneous Coronary Intervention - Phase III, Randomized, Double-Blind Study -

机译:普拉格雷(Prasugrel),第三代P2Y12受体拮抗剂,在接受选择性经皮冠状动脉介入治疗的冠状动脉疾病患者中-III期,随机,双盲研究-

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Prasugrel is being developed in Japan as an antiplatelet therapy for use during percutaneous coronary intervention (PCI). Up to 70% of Japanese patients with coronary artery disease undergo elective PCI. The PRASugrel For Japanese PatIenTs with Coronary Artery Diseases Undergoing Elective PCI (PRASFIT-Elective) study investigated the efficacy and safety of different prasugrel dosing regimens in Japanese patients undergoing elective PCI.
机译:背景:普拉格雷(Prasugrel)在日本正在开发为抗血小板疗法,可用于经皮冠状动脉介入治疗(PCI)。日本冠心病患者中多达70%接受了选择性PCI。接受选择性PCI的日本冠心病患者的PRASugrel(PRASFIT-Elective)研究调查了不同的prasugrel给药方案对接受选择性PCI的日本患者的疗效和安全性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号